EYEric Ricardo Yonatan

Eric Ricardo Yonatan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric Ricardo Yonatan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Erlangga Saputra Arifin

    School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia

    2 shared publications
  • Louis Fabio Jonathan Jusni

    School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, North Jakarta, Indonesia

    2 shared publications
  • Adeline Pasaribu

    Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

    1 shared publication
  • Alver Prasetya

    Faculty of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Special Capital Region of Jakarta, North Jakarta, Indonesia

    1 shared publication
  • Andrew Ep. Sunardi

    Department of Cardiology, Dr. M. Goenawan Partowidigdo Lungs Hospital, Cisarua, Indonesia

    1 shared publication
  • Clifford Peter Anthony

    Atma Jaya Catholic University of Indonesia, School of Medicine and Health Sciences, Jakarta, Indonesia

    1 shared publication

Latest Publications

  • Open Access

    Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

    by Ikhwan Rinaldi, Eric Ricardo Yonatan, Tasia Esterita

    Purpose: Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low or negative PD‐L1 expression, and in the overall population. Methods: A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted following PRISMA 2020 guidelines. Pooled efficacy and safety outcomes were calculated as hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (CIs). Results: Three RCTs ( n = 1859) were included. Durvalumab and tremelimumab significantly improved overall survival (OS) compared with that of chemotherapy (HR = 0.81, 95% CI: 0.67–0.99) in patients with PD‐L1 < 1%. Progression‐free survival (PFS) and objective response rate (ORR) were not significantly different in the overall population compared with those in the patient cohort. Treatment‐related adverse events (TRAEs) and grade ≥ 3 TRAEs were significantly lower in patients receiving the drug combination (RR = 0.78 and 0.64, respectively), whereas serious TRAEs were higher (RR = 1.41, 95% CI: 1.14–1.74) when compared with those receiving standard chemotherapy. No significant differences were observed in treatment‐related deaths. Conclusions: Durvalumab plus tremelimumab may be a promising alternative to chemotherapy in patients with mNSCLC with low PD‐L1 expression for improving OS, although the PFS and ORR benefits were not significant in the overall population. This combination has a favorable safety profile, although it is associated with a higher risk of serious TRAEs. Further studies are required to confirm these findings. PROSPERO Protocol Registration: CRD420250652760.

  • Do Incretin-Based Therapies Influence the Risk of Cholangiocarcinoma in Type 2 Diabetes Patients? Insights from a Systematic Review and Meta-Analysis

    by Eric Ricardo Yonatan, Louis Fabio Jonathan Jusni, Steven Alvianto, Nicolas Daniel Widjanarko, Steven Yulius Usman, Virly Nanda Muzellina

    Introduction Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is), are widely used in the management of type 2 diabetes mellitus (T2DM). However, concerns have emerged regarding their potential association with an increased risk of cholangiocarcinoma (CCA), and current evidence remains inconclusive. This review aims to evaluate and clarify the association between incretin-based therapies and the risk of CCA in patients with T2DM. Methods This review followed PRISMA 2020 guidelines and was registered in PROSPERO (CRD42025641616). A comprehensive search was performed across PubMed, ProQuest, EBSCOhost, Wiley, and SAGE databases. Eligible observational studies reporting the association between incretin-based therapies and CCA were included. Study quality was assessed using the Newcastle–Ottawa Scale (NOS). Pooled hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using RevMan with a random-effects model. Result Four studies (three cohort and one case–control) were included. The pooled HRs showed no significant association between incretin-based therapies and CCA risk, with estimates of 1.07 (95% CI: 0.70–1.63) for GLP-1RAs and 1.05 (95% CI: 0.83–1.34) for DPP-4Is. Pooled RR analyses yielded similarly non-significant results. All included studies were assessed as having a low risk of bias according to the NOS. Conclusion Incretin-based therapies do not significantly increase the risk of CCA in T2DM patients. Within the limitations of the available observational evidence, these findings provide reassurance regarding their safety profile, while highlighting the need for ongoing pharmacovigilance and further large-scale studies to confirm these results.


    • 1 October 2025
      • Vol. 57  (4) , 559-569

    Typhoid Fever in Indonesia: Pitfalls in the Diagnosis of Typhoid Fever.

    by Eric Ricardo Yonatan, Adeline Pasaribu, Leonard Nainggolan, Khie Chen Lie

    Typhoid fever remains a major public health issue in Indonesia, with its true burden likely underreported due to diagnostic challenges. The clinical manifestations of typhoid fever are often nonspecific and overlap with other endemic febrile illnesses such as dengue, leptospirosis, and rickettsial infections, leading to frequent misdiagnosis. Although blood culture and PCR are the gold standards, their limited accessibility in Indonesia has resulted in reliance on suboptimal diagnostic tools such as the Widal test and TUBEX TF. Recent advances, including the Nelwan Score and CRP-based differentiation, have shown promise in improving early clinical screening. Furthermore, antibody-based proteomic diagnostics offer enhanced accuracy but remain largely confined to research settings. A combined approach utilizing validated clinical scores, affordable biomarkers, and selective use of serological tests is essential to improve diagnostic accuracy and patient care. Misdiagnosis not only endangers patient outcomes but also contributes to inappropriate antibiotic use, accelerating the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Salmonella Typhi. Resistance to first-line antibiotics and fluoroquinolones has been increasingly reported in Indonesia, although some regions still demonstrate preserved susceptibility. Cautious and evidence-based antibiotic prescribing is therefore critical to mitigating resistance. This article underscores the urgent need to strengthen diagnostic strategies and antimicrobial stewardship to address the persistent challenge of typhoid fever in Indonesia.

  • Open Access

    Efficacy and safety of tislelizumab in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis

    by Eric Ricardo Yonatan, Surya Sinaga Immanuel, Erlangga Saputra Arifin, Louis Fabio Jonathan Jusni, Riki Tenggara, Mario Steffanus, Delia Anastasia Tirtadjaja

    Background: Tislelizumab, a PD-1-targeting monoclonal antibody, can potentially treat advanced esophageal squamous cell carcinoma (ESCC). Using pooled clinical data, this study evaluates Tislelizumab's efficacy and safety in advanced ESCC. Methods: This review followed PRISMA guidelines, with a comprehensive search conducted across PubMed, ProQuest, EBSCOhost, and Google Scholar for clinical trials involving ESCC patients treated with Tislelizumab. Primary endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). We evaluated the study quality using the Cochrane Risk of Bias and ROBINS-I tools. Data extraction and pooling were performed using R for single-arm studies and RevMan 5.4 for RCTs. Outcomes were analyzed using pooled medians, hazard ratios for OS and PFS, and relative risks for ORR, DCR, and adverse events. Results: Four studies with 1,202 patients met inclusion criteria. The risk of bias was low to moderate. Pooled data indicate a median OS of 8.6 months and PFS of 4.75 months in the Tislelizumab group, with an overall ORR of 0.40 (95% CI: 0.20–0.61) and DCR of 0.64 (95% CI: 0.36–0.88). Tislelizumab significantly improved OS (HR 0.68, 95% CI: 0.59–0.78, p < 0.0001), PFS (HR 0.71, 95% CI: 0.54–0.93, p = 0.01), ORR (RR 1.65, 95% CI: 1.22–2.24, p = 0.001), and DCR (RR 1.11, 95% CI: 1.04–1.18, p = 0.001) compared to standard chemotherapy. Pooled rates of grade 3 or more AEs and serious AEs were 0.56 (95% CI: 0.17–0.92) and 0.28 (95% CI: 0.10–0.50), respectively. There were no significant differences in grade 3 and serious AEs between Tislelizumab and standard chemotherapy. The most common AEs reported included hematologic toxicities, gastrointestinal issues, metabolic disturbances, and biochemical abnormalities. Conclusion: Tislelizumab improves survival and response in advanced ESCC patients, particularly when combined with chemotherapy, with an acceptable safety profile. These findings support its continued use in ESCC, though further investigation is warranted due to the limited number of studies. Trial registration: CRD42024564367.

  • Open Access

    Diagnosis dan Tata Laksana Graves’ Disease

    by Eric Ricardo Yonatan

    Graves’ disease adalah penyebab utama (60%-80%) kasus hipertiroidisme. Faktor risiko penyakit meliputi genetik, lingkungan, dan imunologis, dengan prevalensi lebih tinggi pada wanita. Diagnosis berdasarkan anamnesis dan pemeriksaan fisik yang dapat dibantu dengan indeks Wayne, serta pemeriksaan penunjang, meliputi pemeriksaan laboratorium fungsi tiroid, pemeriksaan antibodi, thyroid scan, atau color-doppler ultrasonography. Tata laksana terdiri dari pemberian obat anti-tiroid, radioactive iodine treatment (RAI), dan pembedahan. Komplikasi Graves’ disease meliputi Graves ophthalmopathy, dermopati tiroid, pengaruh pada sistem kardiovaskular, hingga krisis tiroid. Prognosis bergantung dari kemungkinan remisi dan relaps, kemungkinan remisi lebih tinggi pada dewasa dibanding anak-anak.


  • Open Access

    Redefining treatment paradigms: Early use of dapagliflozin and empagliflozin in acute heart failure – a systematic review and meta-analysis of randomized controlled trials

    by Surya S. Immanuel, Eric R. Yonatan, Gabriel Tandecxi, Clifford P. Anthony, Janice Z. Chan, Andrew Ep. Sunardi, Ira Posangi, Victor Bandana

    Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have proven to significantly reduce mortality and rehospitalization in heart failure with reduced ejection fraction (HFrEF). Supported by the 2023 European Society of Cardiology (ESC) guidelines and the safety, tolerability, and efficacy of rapid optimization of heart failure (STRONG-HF) trial, SGLT2i offer improved outcomes with a favorable safety profile, emphasizing their pivotal role in HFrEF management. The aim of this study was to evaluate early initiation with dapagliflozin and empagliflozin, focusing on their efficacy and safety in acute heart failure (AHF). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched seven databases for randomized controlled trials on SGLT2i in AHF (2019–2024). Outcomes included all-cause mortality, heart failure (HF)-related events, all-cause rehospitalization, length of hospital stay, diuretic response, serum electrolytes, and adverse events (AEs). The Cochrane Risk of Bias 2 tool was used. Data were analyzed using a random-effects model and presented as standardized mean differences and risk ratios with 95% confidence intervals. A subgroup analysis was conducted based on intervention. Nine studies encompassing 1,417 patients with a generally low risk of bias were included. Initiating SGLT2i within five days of admission significantly reduced in-hospital all-cause mortality risk by 42% and in-hospital worsening HF during rehospitalization by 39%. SGLT2i also significantly reduced serious AEs risk by 27%. No significant differences were found in other outcomes, including specific AEs (acute kidney injury, hepatic injury, symptomatic hypotension, hypoglycemia, urinary tract infections, and diabetic ketoacidosis). The analysis showed homogeneity, with no significant differences between SGLT2i. The study highlights that initiating SGLT2i within five days of admission significantly reduces all-cause mortality and worsening HF during rehospitalization, with a better safety profile than placebo.


  • Evaluation of fruquintinib’s efficacy and safety in refractory metastatic colorectal cancer: a systematic review and meta-analysis of phase II and III randomized controlled trials

    by Eric Ricardo Yonatan, Rivaldi Ruby, Alver Prasetya, Erlangga Saputra Arifin

    Background Metastatic colorectal cancer (mCRC) remains a significant cause of mortality despite advancements in treatments. Fruquintinib, a potent VEGFR inhibitor, has shown promise as an advanced therapy for mCRC. This review evaluates the efficacy and safety of fruquintinib compared to placebo in patients with refractory mCRC, focusing on Phase II and III trials. Method This study was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A literature search was performed using PubMed, EBSCOHost, ProQuest, and Google Scholar. The analysis of overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety was pooled using hazard ratios (HR) and risk ratios (RR) in RevMan 5.4 software. Results Three RCTs comprising 1,178 patients were included. Fruquintinib significantly improved OS (HR: 0.66; 95% CI 0.57–0.76) and PFS (HR: 0.30; 95% CI 0.26–0.35) compared to placebo. ORR (RR: 5.91; 95% CI 1.09–32.16) and DCR (RR: 3.83; 95% CI 3.00–4.90) were also higher with fruquintinib. Grade 3 or higher adverse events were more frequent with fruquintinib (RR: 1.31; 95% CI 1.02–1.70). No significant difference was observed in serious adverse events or treatment-related deaths. Conclusion Fruquintinib significantly improves survival and tumor response in patients with refractory mCRC. While associated with an increased risk of high-grade adverse events, fruquintinib remains a viable and relatively safe treatment option for mCRC patients. Further studies are needed to confirm its efficacy and safety across diverse populations.